Alex Trebek continued to shine a spotlight on pancreatic cancer until his death. The Jeopardy! host, who died from the disease on Nov. 8, taped a special message for World Pancreatic Cancer Day, which aired during Thursday’s show.
Alex Trebek continued to shine a spotlight on pancreatic cancer until his death. The Jeopardy! host, who died from the disease on Nov. 8, taped a special message for World Pancreatic Cancer Day, which aired during Thursday’s show.
Investors worried about whether a looming government shutdown could slow U.S. stocks' recent surge can take comfort in history: markets have tended to shrug off shutdowns despite their potentially nasty economic impact. Since 1984, the S&P 500 has averaged a 1.3% gain during government shutdowns, having edged lower in only two out of the last 10 instances. The most recent shutdown, which lasted for five weeks, shaved 0.1% and 0.2% from real U.S. gross domestic product in the fourth quarter of 2018 and the first quarter of 2019, respectively, according to the Congressional Budget Office.
NEW DELHI — A chilly breeze whirls through New Delhi in the mornings and the sun is partly obscured by toxic haze, a marker of another winter in the Indian capital. But along the city's borders, this year is visibly and viscerally different. The perpetually busy arterial highways that connect most northern Indian towns to this city of 29 million people now pulse to the cries of “Inquilab Zindabad” — “Long live the revolution.” Tens and thousands of farmers with distinctive, colorful turbans and long, flowing beards have descended upon the city's borders, choking highways in giant demonstrations against new farming laws that they say will open them to corporate exploitation. For more than a week, they’ve marched toward the capital on their tractors and trucks like an army, pushing aside concrete police barricades while braving tear gas, batons and water cannons. Now, on the outskirts of New Delhi, they are hunkered down with food and fuel supplies that can last weeks and threatening to besiege the capital if Prime Minister Narendra Modi’s government doesn't meet their demands to abolish the laws. “Modi wants to sell our lands to corporates,” said one of them, Kaljeet Singh, 31, who travelled from Ludhiana city in Punjab, some 310 kilometres (190 miles) north of New Delhi. “He can’t decide for millions of those who for generations have given their blood and sweat to the land they regard as more precious than their lives.” At night, the farmers sleep in trailers and under trucks, curling themselves in blankets to brave the winter chill. During the day, they sit huddled in groups in their vehicles, surrounded by mounds of rice, lentils and vegetables that are prepared into meals at hundreds of makeshift soup kitchens, in enormous pots stirred with wooden spoons the size of canoe paddles. Anmol Singh, 33, who supports his family of six by farming, said the new laws were part of a larger plan to hand over the farmers' land to big corporations and make them landless. “Modi wants the poor farmer to die of hunger so that he can fill the stomachs of his rich friends,” he said. “We are here to fight his brutal decrees peacefully.” He paused, then reconsidered: “Actually, let him and his ministers take us on. We will give them a bloody nose.” Many of the protesting farmers hail from northern Punjab and Haryana, two of the largest agricultural states in India. An overwhelming majority of them are Sikhs. They fear the laws passed in September will lead the government to stop buying grain at minimum guaranteed prices and result in exploitation by corporations who will push down prices. Many activists and farming experts support their demand for a minimum guaranteed price for their crops. The new rules will also eliminate agents who act as middlemen between the farmers and the government-regulated wholesale markets. Farmers say agents are a vital cog of the farm economy and their main line of credit, providing quick funds for fuel, fertilizers and even loans in case of family emergencies. The laws have compounded existing resentment from farmers, who often complain of being ignored by the government in their push for better crop prices, additional loan waivers and irrigation systems to guarantee water during dry spells. The government has argued the laws bring about necessary reform that will allow farmers to market their produce and boost production through private investment. But farmers say they were never consulted. With nearly 60% of the Indian population depending on agriculture for their livelihoods, the growing farmer rebellion has rattled Modi’s administration and allies. His leaders have scrambled to contain the protests, which are fast resembling last year’s scenes when a contentious new citizenship law that discriminated against Muslims led to demonstrations that culminated in violence. Those demonstrations were much bigger in scale, but the farmers' rumblings are growing fast and gaining widespread support of ordinary citizens who have started joining them in large numbers. Modi and his allies have tried to allay farmers’ fears about the new laws while dismissing their concerns. Some of his party leaders have called the farmers “misguided” and “anti-national,” a label often given to those who criticize Modi or his policies. The government is holding talks with the farmers to persuade them to end their protests, but they have dug in their heels. Farmer Kulwant Singh, 72, said that when he left his home in Haryana for the protests, he gave his wife a garland of flowers for two possible scenarios. “Either I return victorious and she places it around my neck in celebration, or I die here revolting and the same garland is put on my body when it reaches home,” Singh said. Such passions run deep among the protesters who have found social, economic and generational barriers tumbling during the demonstrations. Singh isn't the only one from his family who travelled to New Delhi for what he called “Qilah Fatehi," an Urdu term that translates to “laying a siege.” His son and grandson also accompanied him. “It's a fight for my generation too,” said Amrinder Singh, 16. As demonstrations grow, the protesters have also started to drive a political message home. Not satisfied with Modi's federal policies, many of which have attracted widescale resentment from his critics and minorities, protesting farmers say it's time he stops what they call his “dictatorial behaviour.” “India is in a recession. There are hardly any jobs and our country's secular fabric is in tatters,” said Gurpreet Singh, 26, a biotechnology student who comes from a farming family. “At a time when India needs a healing touch, Modi is coming up with divisive, controversial laws. This is unacceptable and defies our constitutional values.” Modi's second term in power since May 2019 has been marked by several convulsions. The economy has tanked, social strife widened, protests have erupted against discriminatory laws and his government has been questioned over its response to the pandemic. The farmer protests present a new challenge for the government. The protesters' desire to stand up to Modi and his policies extends to a sexagenarian farmer couple who drove 250 kilometres (155 miles) from Chandigarh city in a hatchback Sunday to participate in the demonstrations. Dharam Singh Sandhu, 67, and Vimaljeet Kaur, 66, are spending nights in their car parked near the protest site. In the morning, they share breakfast at a makeshift soup kitchen. The latter part of the day is spent taking part in the demonstrations. “Our land is our mother. If we can’t protect it then we have no right to live," Sandhu said about the protests. His wife spoke passionately of a larger purpose as she made her way to the protest site through a stream of vehicles honking incessantly to get past congested traffic. “Our country is like a bunch of flowers, but Modi wants it to be of the same colour. He has no right to do that. I am here to protest against that mindset," Kaur said. As Kaur walked hand in hand with her husband, a great cry emerged from one of the vehicles: “Inquilab Zindabad.” The crowd turned and followed their gaze toward a young man with a black beard who held up his fist through the car's window. The protesters, including Kaur, roared back: “Inquilab Zindabad!" Sheikh Saaliq, The Associated Press
Police say the explosion at a water recycling centre in Avonmouth happened in a biosolid treatment silo, though the cause of the blast is unknown.
The Automotive Software Market will grow by $ 10.70 bn during 2020-2024
New Delhi [India], December 4 (ANI): India reported less than 50,000 cases for the 27th day in a row with 36,594 new COVID-19 infections in the last 24 hours, according to the Union Ministry of Health and Family Welfare's data on Friday.
Celebrities and opposition MPs have lobbied against the deportation of 36 jail prisoners to Jamaica.
Going wild? A radical green plan for Nottingham's unloved shopping centreCould replacing empty shops with wetlands, woodlands and meadows offer a new model for cities? * Coronavirus – latest updates * See all our coronavirus coverage
Houston (Texas) [US], December 4 (ANI): A new study published in Psychological Science has found that the changes during young adulthood indicate personality growth which can be beneficial for career growth.
Image source: The Motley Fool. Zuora, Inc. (NYSE: ZUO)Q3 2021 Earnings CallDec 03, 2020, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to Zuora's third-quarter fiscal 2021 earnings conference call.
Good afternoon, and thank you for joining us today for our discussion of Ulta Beauty's results for the third quarter of fiscal 2020. Hosting today's call are Mary Dillon, chief executive officer; and Scott Settersten, chief financial officer.
AstraZeneca and Oxford University have given conflicting accounts of how they came upon the most effective dosing pattern for their COVID-19 vaccine, a rare instance of public dissension between major institutions collaborating on a pivotal project. The half-dose pattern was found to be 90% effective, versus the 62% success rate of the two-full-dose main study, based on interim data. AstraZeneca's research chief told Reuters 10 days ago, when interim trial data was released, the half-dose was given inadvertently as a first shot to some trial participants, and emerged as a stroke of fortune - "serendipity" - that scientists expertly harnessed.
The high street is doomed? Tell that to the people queuing outside Primark. We are rediscovering shopping as a social activity under Covid restrictions – but only the government can give retail a chance
The High Low goes out on a high – podcasts of the week. Pandora Sykes and Dolly Alderton bow out after four years hosting their hit show. Plus: fly-on-the-wall chats with Pharrell Williams, and an accessible look at the climate emergency
Pollutionwatch: toxic threat from wood burning and tyre dust. Swiss study analyses different sources of air pollution – the fourth largest risk factor for early death
Radical reassessment needed to hit net zero emissions by 2050, says NAO. Watchdog finds UK is projected to fail to meet targets aimed at achieving climate goal
‘He will be remembered as a hero’: Denzel Washington and Viola Davis on Chadwick Boseman. The late actor knew he had a terminal illness during the filming of Ma Rainey’s Black Bottom – and turned in an astonishing performance
UBS Group AG said on Friday it appointed Chief Operating Officer and President EMEA Sabine Keller-Busse as president of UBS Switzerland, while Iqbal Khan, co-president of global wealth management, will succeed Keller-Busse as president EMEA, in addition to his current role. Keller-Busse, who joined UBS in 2010 and was named Group COO in 2018, succeeds Axel P. Lehmann who has decided to step down from his current roles as president personal & corporate banking and president UBS Switzerland at the end of January 2021, and will leave the bank after a transition phase at the end of July, UBS said in a statement.
ROTTERDAM, The Netherlands (4 December 2020) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announced the acquisition of two speciality distribution companies in Mexico, Millikan S.A. de C.V. (“Millikan”) and Banner Química S.A. de C.V. (“Banner Química”). “It has been a very active year for our IMCD Mexico team, and we are pleased to maintain our growth momentum with the acquisitions of Millikan and Banner Química in this important Latin American market,” said Marcus Jordan, Americas President, IMCD. “Both companies perfectly complement our existing operations in Mexico and strengthen our technical and commercial offering in a number of core market segments.”Both based in Mexico City, Millikan and Banner Química collectively generated a revenue of USD 15 million in 2019 and add 60 employees to the IMCD Mexico team. This latest development is preceded by the establishment of IMCD Mexico in April 2020, which serves the pharmaceuticals, food, nutrition, and personal care industries. “Joining IMCD puts our company on the global map and we are delighted to share a mutual desire to offer market differentiation through technical expertise and trend-based solutions for the customers we serve,” said Francisco Camacho, General Director, Millikan. Millikan was established in 1998 and offers technical support and commercial expertise to customers in the food, nutrition, pharmaceuticals, and industrial markets. “I anticipate that IMCD’s reputation for professionalism and market proficiency will create new opportunities for innovation and growth for our loyal customers and principal partners,” said Salvador Ramos, General Director, Banner Química. Banner Química has delivered formulatory solutions for the personal care and home care industries since 2009. The acquisition of Millikan and Banner Química also enhances IMCD’s technical capabilities through the addition of its food and personal care laboratories, further strengthening IMCD’s global network of technical centres.-xxx-Attached, please find the release in pdf format.Attachment * Press Release-IMCD Mexico continues growth momentum with acquisition of Millikan and Banner Quimica
To better serve the North American market WindSim and Cognite product offerings are expanded to include transmission line performance monitoring and evaluation of enhanced current carrying capacity targeted at wind plant integrationAUSTIN, Texas, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cognite, a global industrial AI software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world, announces a new collaboration with WindSim, a leading provider and pioneer of Computational Fluid Dynamics (CFD) based Wind Farm Design Tools (WFDT) utilized for the design of wind farms both onshore and offshore. This partnership will maximize new and existing asset performance, increase energy efficiency, and reduce transmission bottlenecks and costs in the power and utilities industry. This offering is a direct response to the need for advanced software that enables power & utility customers to better adapt their operations to dynamic industry change.WindSim’s simulation technology makes industrial data valuable to engineering and operations teams so they can plan more effective offshore wind farms and maximize the efficiency of existing transmission and distribution infrastructure. This level of advanced analytics is supported by Cognite’s data operations and contextualization platform called Cognite Data Fusion (CDF), which contextualizes industrial data and makes it actionable. Combined, this offering puts simulation analysis in context with real-world data and operational decisions.“The application of CFD technology and other advanced methods in the wind energy industry is an important part of the decisioning process for greenfield and brownfield projects,” said Donna Rennemo, CEO of WindSim. “With Cognite Data Fusion, WindSim’s unique solution can leverage high-fidelity data and paint a clearer picture of the potential decision outcomes. Making data do more so that it is available, processed, and simulated well, helps wind farm owners and transmission owners and operators optimize operations, reduce costs and reduce investment risks.”Trygve Ronningen, Chief Operating Officer of Cognite North America adds, “This collaboration with WindSim deploys an important layer of value and clarity on top of inherently messy industrial data. By enabling WindSim to leverage prepared data and scale with less effort, organizations can more effectively move from proofs of concept to productized, high-ROI deployment.”Webinar Alert: Register here to attend an upcoming webinar and learn more from Cognite and WindSim about how to enable flexible, efficient transmission operations on December 16th, 2020 3pm - 4pm (CST) / 10pm - 11pm (CET)About WindSim WindSim develops and delivers advanced software solutions and consulting services that help worldwide wind energy industry leaders design more profitable wind farms. WindSim, the company's flagship product, is a world-class software solution based on Computational Fluid Dynamics (CFD) that combines advanced numeric processing with compelling 3D visualization in a user-friendly interface. Founded in 1993, WindSim is privately-held and venture-backed.About CogniteCognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital data driven transformation of heavy-asset industries around the world. Our core product, Cognite Data Fusion (CDF), is an industrial data operations and contextualization platform, putting raw data into real-world industrial context, enabling rapid application & solution creation at scale. CDF powers companies with contextualized OT/IT/ET data to develop solutions that increase safety, sustainability, efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedataMedia Contacts: Michelle Holford - Cognite +4748290454 (Norway) +1512 744 3420 (US) email@example.com \------ Donna Rennemo - WindSim Phone: +1 805 216 0785 firstname.lastname@example.org
* Preliminary data from the Phase 1 trial are expected first half 2021 * Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced dosing of the first patient of the Phase 1 IMMUNICY-1 trial of CYAD-211, the Company’s novel, short hairpin RNA (shRNA)-based anti-B-cell maturation antigen (BCMA) candidate for the treatment of relapsed/refractory multiple myeloma (r/r MM). “Despite the introduction of several new treatment options over the past few years, multiple myeloma remains a devastating disease with a high unmet need for new therapies. We are proud to participate in the IMMUNICY-1 trial which will evaluate CYAD-211 in the treatment of relapsed or refractory multiple myeloma patients,” said professor Dr. Sébastien Anguille, CAR T specialist at the Antwerp University Hospital (UZA), Edegem, Belgium. “Based on the encouraging preclinical data, we believe this new allogeneic CAR T targeting BCMA has the potential to become an important therapy for such a challenging patient population.”Frédéric Lehmann, VP of Clinical Development & Medical Affairs at Celyad Oncology, added, “Dosing the first patient with CYAD-211 marks another major milestone to systematically advance our pipeline of non-gene edited allogeneic CAR T candidates. BCMA is highly expressed in multiple myeloma patients and we hope to see a positive clinical benefit with our approach of targeting BCMA with our first-in-class CAR T which is underpinned by our shRNA technology. Enrollment in the IMMUNICY-1 trial will continue over the coming months and we expect to report proof-of-concept data from the initial dose cohorts of the trial during the first half of 2021.”Financial UpdateThe Company received €3.4 million in non-dilutive funding from the SPW-Recherche of the Walloon Region, which will support the development of CYAD 211. Under the terms of this funding, the Company was awarded non-dilutive funding in the form of recoverable cash advances (‘avances récupérables’). The regional funding is associated with the Company’s specific research and development programs. Under the applicable conditions, the recoverable cash advance is reimbursable over the economic life of the projects. Thirty percent is refundable based on a fixed reimbursement schedule of 20 years, while the balance is refunded under the form of royalties over the same period.The Company confirms its previous guidance that its existing treasury position should be sufficient, based on the current scope of activities, to fund operating expenses and capital expenditure requirements into the third quarter of 2021.About CYAD-211CYAD-211 is an investigational, shRNA-based allogeneic CAR T candidate for the treatment of r/r MM. CYAD-211 is engineered to co-express a BCMA targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T cell receptor complex. In July 2020, Celyad Oncology announced FDA clearance of its IND application for CYAD-211.About IMMUNICY-1 Phase 1 TrialThe open-label, dose-escalation trial will evaluate the safety and clinical activity of a single infusion of CYAD-211 following preconditioning chemotherapy cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²) in patients with relapse or refractory multiple myeloma. The trial will evaluate multiple dose levels of CYAD-211: 3x107, 1x108 and 3x108 cells per infusion. For more information, please visit www.clinicaltrials.gov, study identifier number NCT04613557. About shRNA PlatformCelyad Oncology is focused on the development of its proprietary non-gene edited allogeneic shRNA technology platform. The shRNA platform coupled with the Company’s All-in-One vector approach provides flexibility, versatility, and efficiency to the design of novel, off-the-shelf CAR T candidates through a single step engineering process. Next-generation candidates exploring the breadth and depth of the Celyad Oncology shRNA platform are currently under preclinical development. In 2018, Celyad Oncology signed an exclusive agreement with Horizon Discovery Group for the use of its SMARTvector shRNA technology for the development of allogeneic CAR T therapies.About Celyad OncologyCelyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.Forward-Looking StatementThis release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the clinical development of CYAD-211 and timing of expected data from the Phase 1 IMMUNICY-1 trial and the expected use of the non-dilutive funding from the Walloon Region. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.Investor and Media Contacts:Sara Zelkovic Director Communications & Investor Relations Celyad Oncology email@example.comDaniel Ferry Managing Director LifeSci Advisors, LLC firstname.lastname@example.orgSource: Celyad Oncology SA